Key result
Familial hypercholesterolemia remains underdiagnosed across Latin America, with no causal mutation found in ~50% of cases.
Why the study?
The prevalence and characteristics of familial hypercholesterolemia in Latin American countries are largely unknown, with limited data on genetics, screening, and management.
Systematic Review
Yes
Reveals major data gaps on FH in Latin America; extends global understanding while leaving region-specific screening and management needs open.
The burden caused by familial hypercholesterolemia (FH) varies among countries and ethnic groups. The prevalence and characteristics of FH in Latin American (LA) countries is largely unknown. We present a systematic review (following the PRISMA statement) of FH in LA countries. The epidemiology, genetics, screening, management, and unique challenges encountered in these countries are discussed. Published reports discussing FH in Hispanic or LA groups was considered for analysis. Thirty studies were included representing 10 countries. The bulk of the data was generated in Brazil and Mexico. Few countries have registries and there was little commonality in FH mutations between LA countries. LDL receptor mutations predominate; APOB and PCSK9 mutations are rare. No mutation was found in an FH gene in nearly 50% of cases. In addition, some country-specific mutations have been reported. Scant information exists regarding models of care, cascade screening, cost, treatment effectiveness, morbidity, and mortality. In conclusion, FH is largely underdiagnosed and undertreated in the LA region. The genetic admixture with indigenous populations, producing mestizo's groups, may influence the mutational findings in Latin America. Potential opportunities to close gaps in knowledge and health care are identified.
No takes yet. Share an insight, caveat, or question.
Mehta et al. (2016) conducted a systematic review in Familial hypercholesterolemia. Familial hypercholesterolemia was evaluated. Familial hypercholesterolemia is largely underdiagnosed and undertreated in Latin America, with LDL receptor mutations predominating and no FH gene mutation found in nearly 50% of cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: